This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  


EVENT: Life Sciences Business Support - Lunch & Learn

  Join us for a complimentary lunch and an informative session with the Department for Business and Trade (DBT), showcasing the range of free support services available to UK life science companies.   Wednesday 4 June, 12.30pm – 1.30pm   What to Expect: An overview of the UK Government’s Business Strategy Insights into Government Funding Opportunities Guidance on International Market Access (ESS Overseas Support) A summary... Read more

Campaign for Cowley Branch Line launched

The Campaign for Cowley Branch Line is being launched today to advocate for the re-opening of the Cowley Branch Line to passengers. The rail project would transform public transport for local communities, unlock new housing, create new jobs and support Oxford’s net-zero ambitions. The campaign, led by The Oxford Science Park, ARC Oxford and the Ellison Institute of Technology, is calling on local businesses to lend their support in a... Read more

Oxford Science Park team takes on OX5 RUN for Oxford Children’s Hospital

A team from The Oxford Science Park laced up its running shoes on Sunday to take part in the OX5 RUN at Blenheim Palace. The annual five-mile charity run supports the Oxford Children's Hospital and other Trust departments that care for young patients, including the Emergency Departments, the Paediatric Intensive Care Unit (PICU), and the Horton and Nuffield Orthopaedic Centre. Under clear skies and amidst breathtaking scenery, the team... Read more

Sitryx initiates Phase1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219

Sitryx Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, has announced the initiation of its first-in-human Phase 1a clinical trial evaluating SYX-5219 for the treatment of atopic dermatitis. This milestone follows the recent Clinical Trial Authorisation (CTA) granted by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).... Read more

Lord Vallance meets science & innovation leaders in Oxford

Science Minister Lord Vallance visited Oxford this week in his new role as the Oxford-Cambridge Growth Corridor Champion. During his visit, Lord Vallance met with representatives from The Oxford Science Park,  The Ellison Institute of Technology and Oxford City Council  at ARC Oxford. He learned about the area’s growing cluster of pioneering organisations, its growth plans and its long-standing support for reopening the Cowley Branch... Read more

The Daubeny Project

Imaginative design, inspiring spaces.